Les activités du CHUV
de psychiatrie
Accueil > Recherche > Centres et unités de recherche > Center for Psychiatric Neurosciences > Unit for Research in Schizophrenia > Lab Members > Kim Q. Do

Kim Q. Do


Tel. +41 21 314 2842

Contact e-mail

Kim Q. Do

Prof. Kim Q. Do is a neurobiologist, director of the Center for Psychiatric Neuroscience (Department of Psychiatry, Lausanne University Hospital) and head of the Unit for Research in Schizophrenia (URS).

Her current major interest lies in bridging basic neuroscience with problems of clinical psychiatry.

In 1999, she set up the URS laboratory and developed an interdisciplinary approach promoting active collaboration between specialists in basic neurobiological research and clinicians.

Her research program is aimed at a better understanding of the causes and mechanisms leading to schizophrenia phenotypes in order to identify markers for early diagnosis, new drug targets as well as preventive and therapeutic measures. Based on an innovative hypothesis, she could demonstrate that oxidative stress/redox dysregulation induced, among others, by glutathione deficit, may represent a "hub" on which both genetic and environmental risk factors converge during neurodevelopment, leading to the impairment of neural connectivity and synchronization, as well as to cognitive deficits. With her collaborators, she showed in several experimental models that, during the development of the brain, this oxidative stress has structural and functional consequences similar to those observed in patients.

As director of the Center for Psychiatric Neuroscience and in addition to her research activities, Prof. Kim Q. Do also works on professional education and public outreach towards better care and cure of major psychiatric disorders.

Prof. Do's research has been supported by institutions such as the Swiss National Science Foundation, the Human Frontier Science Program, NARSAD, as well as various institutions and foundations of the private sector.

Prof. Do received the NARSAD Independent Investigator Award in 2006, and the NARSAD Distinguished Investigator Award in 2010 (with Prof. Patricio O'Donnell).

Selected Publications

  1. Do KQ, Trabesinger AH, Kirsten-Kruger M, Laurer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M. Schizophrenia: glutathione deficit in cerebro spinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience, 12, 3721-3728 (2000)

  2. Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione levels and ascorbic acid associated with dopamine uptake inhibition during rat’s development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiology of disease, 15, 93-105 (2004)

  3. Steullet P, Neijt HC, Cuenod M, Do KQ. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience, 137, 807-819 (2006)

  4. Cabungcal JH, Nicolas D, Kraftsik R, Cuenod M, Hornung J-P*, Do KQ*. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic processes: relevance to schizophrenia. Neurobiology of Disease, 22, 624-637 (2006) *Authors equally responsible for this work

  5. Tosic M, Gysin R, Ott J, Barral S, Bovet P, Deppen ., Gheorghita F, Matthey M-L, Parnas J, Preisig M, Saraga M, Solida A, Timm S, Wang A.G, Werge T, Cuenod M, Do KQ. Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene. The American Journal of Human Genetics, 79, 586-592 (2006)

  6. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do KQ. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proceedings of the National Academy of Sciences USA, 104, 16621-16626 (2007)

  7. Lavoie S*, Murray MM*, Deppen P, Knyazeva M, Berk M, Boulat O, Bovet P, Conus P, Copolov D, Fornari E, Meuli RA, Solida A, Vianin P, Cuenod M, Buclin T, Do KQ. A glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 33, 2187-2199 (2008) *Authors equally responsible for this work

  8. Steullet P, Lavoie S, Guidi R, Kraftsik R, Cuénod M, Do KQ. Intracellular glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodyne receptors. Free Radical Biology and Medecine, 44, 1042-1054 (2008)

  9. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush A. N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A Double-Blind, Randomized, Placebo-Controlled Trial. Biological Psychiatry, 64, 361-368 (2008)

  10. Do KQ, Cabungcal JH, Frank A, Gysin R, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment and schizophrenia. Current Opinion in Neurobiology, 19, 220–230 (2009)

  11. Do KQ, Bovet P, Cabungcal JH., Conus P, Gysin R, Lavoie S, Steullet P, Cuenod M. Redox dysregulation in schizophrenia: Genetic susceptibility and pathophysiological mechanisms. Handbook of neurochemistry and molecular neurobiology, 3rd edition, edited by A Lajtha, Vol 27. Editors D. C. Javitt, J.T. Kantrowitz, Springer, New York, Vol. Schizophrenia, 286-311 (2009)

  12. Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Ying C, Dalton TP, Cuenod M, Do KQ. Chronic Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations and Related Behaviors. Journal of Neuroscience, 30 (7), 2547-2558 (2010)

  13. Steullet P, Cabungcal JH, Kulak A, Cuenod M, Schenk F, Do KQ. Glutathione deficit in animal models of schizophrenia. In: Animal Models Of Schizophrenia and Related Disorders, edited by P. O’Donnell, Humana Press, New York, 149-188 (2011)

  14. Duarte JMN*, Kulak A*, Gholam-Razaee MM, Cuenod M, Gruetter R, Do KQ. N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development. Biological Psychiatry, 71 (11), 1006-1014 (2012) *Authors equally responsible for this work

  15. Kulak A, Steullet P, Cabungcal JH, Werge T, Ingason A, Cuenod M, Do KQ. Redox Dysregulation in the Pathophysiology of Schizophrenia and Bipolar Disorder: Insights from Animal Models. Antioxidants & Redox Signaling, 18 (12), 1428-1443 (2013)

  16. Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-Life Insults Impair Parvalbumin Interneurons via Oxidative Stress: Reversalby N-Acetylcysteine. Biological Psychiatry, 73 (6), 574-582 (2013)

  17. Cabungcal JH, Steullet P, Morishita H, Kraftsik R, Cuenod M, Hensch TK, Do KQ. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proceedings of the National Academy of Sciences USA, 110 (22), 9130-9135 (2013)

  18. Baumann PS, Crespi S, Marion-Veyron R, Solida A, Thonney J, Favrod J, Bonsack C, Do KQ, Conus P. Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne): implementation of an early intervention programme for psychosis in Switzerland. Early Intervention in Psychiatry, 7 (3), 322-328 (2013)

Complete List of Publications